What has changed in the last year as diabetes technology developers continue to innovate and advance their offerings? We are seeing the industry form an intriguing niche at the intersection of medtech and consumer devices. Various companies around the world are delivering numerous options when it comes to the type of technology they want to […]
Dexcom
Dexcom beats Street in Q2, raises guidance as it plans for 15-day G7 launch this year
Dexcom (Nadsaq:DXCM) today reported second-quarter financial results that came in ahead of the consensus forecast. The company also announced a planned CEO transition — read more about that HERE. Shares of DXCM sat unchanged at $89.06 apiece in post-market trading today. (They fell by more than 9% the next day, July 31, to $80.88 apiece.) […]
Dexcom to promote COO Jake Leach to CEO, succeeding Kevin Sayer
Dexcom (Nadsaq:DXCM) announced today that Jake Leach will succeed Kevin Sayer as CEO, effective Jan. 1, 2026. Leach, the company’s president and COO, will take over the corner office as part of the company’s planned succession process. Sayer, who served in the CEO role for more than a decade after assuming the post in January […]
Dexcom launches AI-powered meal logging for CGM users
Dexcom (Nadsaq:DXCM) announced today that it released a new AI-powered photo meal logging feature for its Stelo platform. Stelo, the first FDA-cleared over-the-counter glucose biosensor, joins the G7 continuous glucose monitor (CGM) in offering this new feature. Smart Food Logging encourages and enables users to log meals more consistently through the use of just a […]
Dexcom updates CGM receiver recall that led to serious adverse events
Dexcom (Nasdaq:DXCM) has issued an update related to a recall for its continuous glucose monitor (CGM) components. Last month, the FDA disclosed Dexcom’s recalls related to its Dexcom One and One+ offerings and the G6 and G7 CGMs. The One and One+ systems, which are mainly the company’s commercial CGM offering outside the U.S., feature the established G6 and G7 sensors […]
The biggest diabetes tech stories out of ADA 2025
The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]
Dexcom continues advances in AI for CGM, type 2 diabetes awareness
As one of the leaders in continuous glucose monitoring (CGM) technology, Dexcom (Nadsaq:DXCM) continues to expand its capabilities. The company has hit a number of milestones recently, including updated CGMs, new AI capabilities, expanded partnerships and more. Speaking to Drug Delivery Business News at the American Diabetes Association’s 85th Scientific Sessions in Chicago, Dexcom President and […]
Dexcom shares U.S. report on CGM benefits for type 2 diabetes
Dexcom (Nasdaq:DXCM) has shared a new report highlighting access and attitudes toward type 2 diabetes in the U.S. The company released its report — “Dexcom State of Type 2 Report: Access and Attitudes Across the United States” — ahead of the American Diabetes Association’s 85th Scientific Sessions in Chicago. Findings provide insights into perceptions around […]
Dexcom has a Class I CGM receiver recall
The FDA’s recall database today posted notices related to a Class I recall for continuous glucose monitor (CGM) components made by Dexcom (Nasdaq:DXCM). Dexcom’s recalls relate to its Dexcom One and One+ offerings and the G6 and G7 CGMs. The One and One+ systems, which are mainly the company’s commercial CGM offering outside the U.S., feature […]
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
Insulet (Nasdaq:PODD) today announced the compatibility of its Omnipod 5 App for iPhone with Dexcom G7 continuous glucose monitor (CGM). The latest integration combines the benefits of the companies’ latest technologies, all conveniently controlled from an iPhone. Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM, such as G7. It […]
